المؤلفون: Wu C.-Y., Zhang Y., Liang L., Wu J., Paton V., Millward M., Keam B., Jameson M., Hou M.-M., Kang Y.-K., Markman B., Lu C.-H., Rau K.-M., Lee K.-H., Horvath L., Friedlander M., Hill A., Sandhu S., Barlow P., Desai J., Deva S., Lee J.S., Lin C.-C., Yen C.-J., Chao Y.

مصطلحات الفهرس: hypercalcemia/si [Side Effect], hyperglycemia/si [Side Effect], hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hyponatremia/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], loss of appetite/si [Side Effect], lower respiratory tract infection/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, maximum tolerated dose, melanoma/dt [Drug Therapy], merkel cell carcinoma/dt [Drug Therapy], microsatellite instability, monotherapy, multiple cycle treatment, nausea and vomiting/si [Side Effect], non small cell lung cancer/dt [Drug Therapy], optimal drug dose, ovary carcinoma/dt [Drug Therapy], pancreas cancer/dt [Drug Therapy], phase 1 clinical trial, pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, rash/si [Side Effect], recommended drug dose, renal cell carcinoma/dt [Drug Therapy], retrospective study, sepsis/si [Side Effect], skin carcinoma/dt [Drug Therapy], small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], time to maximum plasma concentration, treatment response time, triple negative breast cancer/dt [Drug Therapy], upper gastrointestinal bleeding/si [Side Effect], bilirubin/ec [Endogenous Compound], new drug/ct [Clinical Trial], new drug/do [Drug Dose], new drug/dt [Drug Therapy], new drug/to [Drug Toxicity], new drug/iv [Intravenous Drug Administration], new drug/pk [Pharmacokinetics], new drug/pv [Special Situation for Pharmacovigilance], programmed death 1 ligand 1/ec [Endogenous Compound], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cr [Drug Concentration], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/to [Drug Toxicity], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/pk [Pharmacokinetics], tislelizumab/pv [Special Situation for Pharmacovigilance], tislelizumab/tm [Unexpected Outcome of Drug Treatment], immunohistochemical test kit, VENTANA PD-L1 (SP263), maximum concentration, adult, aged, anemia/si [Side Effect], antineoplastic activity, area under the curve, article, ascites/si [Side Effect], backache/si [Side Effect], bile duct carcinoma/dt [Drug Therapy], body weight disorder/si [Side Effect], clinical outcome, cohort analysis, colitis/si [Side Effect], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dosage form comparison, drug dose escalation, drug dose regimen, drug efficacy, drug half life, drug safety, drug tolerability, drug withdrawal, dysphagia/si [Side Effect], dyspnea/si [Side Effect], esophagus cancer/dt [Drug Therapy], esophagus carcinoma/dt [Drug Therapy], fatigue/si [Side Effect], female, follow up, gastrointestinal stromal tumor/dt [Drug Therapy], head and neck squamous cell carcinoma/dt [Drug Therapy], human, hyperbilirubinemia/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29145
Journal for ImmunoTherapy of Cancer
Click here for full text options
LibKey Link

المؤلفون: Tramontana A.R., Tong S.Y.C., Lye D.C., Yahav D., Sud A., Robinson J.O., Nelson J., Archuleta S., Roberts M.A., Cass A., Paterson D.L., Foo H., Paul M., Guy S.D., Runnegar N., Andresen D.N., Anagnostou N.A., Johnson S.A., Chatfield M.D., Cheng A.C., Fowler V.G., Howden B.P., Meagher N., Price D.J., Van Hal S.J., O'Sullivan M.V.N., Davis J.S., Walls G.B., McBride S., Bak N., Ghosh N., Rogers B.A., Ralph A.P., Davies J., Ferguson P.E., Dotel R., McKew G.L., Gray T.J., Holmes N.E., Smith S., Warner M.S., Kalimuddin S., Young B.E.

مصطلحات الفهرس: vancomycin/iv [Intravenous Drug Administration], vancomycin/pv [Special Situation for Pharmacovigilance], daptomycin/iv [Intravenous Drug Administration], acute kidney failure/si [Side Effect], adult, aged, all cause mortality, article, clinical outcome, controlled study, diarrhea/si [Side Effect], drug efficacy, drug fever/si [Side Effect], drug monitoring, drug safety, female, follow up, general practitioner, hospitalization, human, hypertransaminasemia/si [Side Effect], major clinical study, male, methicillin resistant Staphylococcus aureus infection/dt [Drug Therapy], monotherapy, mortality rate, pilot study, priority journal, randomized controlled trial, rash/si [Side Effect], recurrent disease, therapy effect, thrombocytopenia/si [Side Effect], thrombophlebitis/si [Side Effect], treatment duration, treatment failure, cefazolin/ae [Adverse Drug Reaction], cefazolin/cb [Drug Combination], cefazolin/dt [Drug Therapy], cefazolin/iv [Intravenous Drug Administration], cefazolin/pv [Special Situation for Pharmacovigilance], cloxacillin/ae [Adverse Drug Reaction], cloxacillin/cb [Drug Combination], cloxacillin/dt [Drug Therapy], cloxacillin/iv [Intravenous Drug Administration], cloxacillin/pv [Special Situation for Pharmacovigilance], daptomycin/ae [Adverse Drug Reaction], daptomycin/cb [Drug Combination], daptomycin/dt [Drug Therapy], daptomycin/pv [Special Situation for Pharmacovigilance], flucloxacillin/ae [Adverse Drug Reaction], flucloxacillin/cb [Drug Combination], flucloxacillin/dt [Drug Therapy], flucloxacillin/iv [Intravenous Drug Administration], flucloxacillin/pv [Special Situation for Pharmacovigilance], vancomycin/ae [Adverse Drug Reaction], vancomycin/cb [Drug Combination], vancomycin/dt [Drug Therapy], Article

URL: JAMA - Journal of the American Medical Association
Click here for full text options
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
Click here for full text options
LibKey Link

المؤلفون: Wong A.

مصطلحات الفهرس: bone marrow suppression/si [Side Effect], China, coma/si [Side Effect], convulsion/si [Side Effect], coronavirus disease 2019/dt [Drug Therapy], diarrhea/si [Side Effect], drug efficacy, drug overdose, drug research, evidence based medicine, gastrointestinal symptom/si [Side Effect], headache/si [Side Effect], heart arrhythmia/si [Side Effect], human, hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hypotension/si [Side Effect], kidney dysfunction/si [Side Effect], liver injury/si [Side Effect], morbidity, mortality, nonhuman, pancreatitis/si [Side Effect], pandemic, patient safety, priority journal, QT prolongation/si [Side Effect], rash/si [Side Effect], self medication, treatment outcome, virus load, virus transmission, activated carbon/dt [Drug Therapy], azithromycin/ae [Adverse Drug Reaction], drug intoxication/dt [Drug Therapy], azithromycin/cb [Drug Combination], azithromycin/dt [Drug Therapy], azithromycin/pv [Special Situation for Pharmacovigilance], ceftriaxone/cb [Drug Combination], ceftriaxone/dt [Drug Therapy], ceftriaxone/pv [Special Situation for Pharmacovigilance], chloroquine/ae [Adverse Drug Reaction], chloroquine/cb [Drug Combination], chloroquine/do [Drug Dose], chloroquine/dt [Drug Therapy], article, atrioventricular block/si [Side Effect], bleeding/si [Side Effect], chloroquine/pv [Special Situation for Pharmacovigilance], colchicine/do [Drug Dose], colchicine/dt [Drug Therapy], colchicine/to [Drug Toxicity], colchicine/pv [Special Situation for Pharmacovigilance], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/cb [Drug Combination], hydroxychloroquine/do [Drug Dose], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pv [Special Situation for Pharmacovigilance], ivermectin/do [Drug Dose], ivermectin/dt [Drug Therapy], ivermectin/to [Drug Toxicity], lopinavir plus ritonavir/ae [Adverse Drug Reaction], lopinavir plus ritonavir/do [Drug Dose], lopinavir plus ritonavir/dt [Drug Therapy], lopinavir plus ritonavir/to [Drug Toxicity], lopinavir plus ritonavir/pv [Special Situation for Pharmacovigilance], remdesivir/ae [Adverse Drug Reaction], remdesivir/dt [Drug Therapy], remdesivir/pv [Special Situation for Pharmacovigilance], thalidomide/do [Drug Dose], thalidomide/dt [Drug Therapy], thalidomide/to [Drug Toxicity], thalidomide/pv [Special Situation for Pharmacovigilance], tocilizumab/ae [Adverse Drug Reaction], tocilizumab/dt [Drug Therapy], tocilizumab/pv [Special Situation for Pharmacovigilance], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29200
EMA - Emergency Medicine Australasia
Click here for full text options
LibKey Link

المؤلفون: Misso M., Garad R., Oberfield S.E., Hoeger K.M., Witchel S.F., Teede H., Pena A.S., Vogiatzi M.G., Dabadghao P.

مصطلحات الفهرس: hypertransaminasemia/si [Side Effect], lifestyle modification, menarche, menstrual cycle, menstrual irregularity/dt [Drug Therapy], nausea/si [Side Effect], nutritional counseling, obesity/pc [Prevention], obesity/th [Therapy], ovary polycystic disease/di [Diagnosis], ovary polycystic disease/dt [Drug Therapy], ovary polycystic disease/th [Therapy], physical activity, practice guideline, primary amenorrhea, transition to adult care, vomiting/si [Side Effect], androgen/ec [Endogenous Compound], antiandrogen/dt [Drug Therapy], antiandrogen/pv [Special Situation for Pharmacovigilance], finasteride/ae [Adverse Drug Reaction], finasteride/dt [Drug Therapy], flutamide/ae [Adverse Drug Reaction], flutamide/dt [Drug Therapy], metformin/ae [Adverse Drug Reaction], metformin/cb [Drug Combination], metformin/cm [Drug Comparison], metformin/dt [Drug Therapy], metformin/pv [Special Situation for Pharmacovigilance], Muellerian inhibiting factor/ec [Endogenous Compound], oral contraceptive agent/cb [Drug Combination], oral contraceptive agent/cm [Drug Comparison], oral contraceptive agent/dt [Drug Therapy], oral contraceptive agent/po [Oral Drug Administration], oral contraceptive agent/pv [Special Situation for Pharmacovigilance], spironolactone/ae [Adverse Drug Reaction], spironolactone/dt [Drug Therapy], depression, abdominal pain/si [Side Effect], acne/dt [Drug Therapy], adolescent, alopecia/dt [Drug Therapy], anxiety, article, body weight control, breast development, clinical evaluation, clinical feature, diagnostic accuracy, diagnostic test accuracy study, diarrhea/si [Side Effect], disease severity, eating disorder, echography, evidence based medicine, gastrointestinal disease/si [Side Effect], hirsutism/dt [Drug Therapy], human, hyperandrogenism/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29308
BMC Medicine
Click here for full text options
LibKey Link

المؤلفون: Palmer J., Lum C., Behren A., Tebbutt N.C., Cebon J., Carlino M.S., Klein O., Kee D., Nagrial A., Markman B., Underhill C., Michael M., Jackett L.

مصطلحات الفهرس: cancer patient, nivolumab/iv [Intravenous Drug Administration], nivolumab/pd [Pharmacology], nivolumab/pv [Special Situation for Pharmacovigilance], triacylglycerol lipase/ec [Endogenous Compound], abdominal pain/si [Side Effect], abnormally high substrate concentration in blood/si [Side Effect], adrenal insufficiency/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], aged, anemia/si [Side Effect], antineoplastic activity, article, bile duct carcinoma/dt [Drug Therapy], cancer combination chemotherapy, cancer control, cancer immunotherapy, cancer regression, cancer survival, cancer tissue, clinical article, cohort analysis, colitis/si [Side Effect], controlled study, decreased appetite/si [Side Effect], diarrhea/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug fatality/si [Side Effect], drug fever/si [Side Effect], drug safety, drug screening, drug withdrawal, endocrine disease/si [Side Effect], fatigue/si [Side Effect], female, gallbladder carcinoma/dt [Drug Therapy], hepatitis/si [Side Effect], human, human tissue, hyperthyroidism/si [Side Effect], hypertransaminasemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypothyroidism/si [Side Effect], immunopathology/si [Side Effect], injection site reaction/si [Side Effect], kidney failure/si [Side Effect], lymphocytopenia/si [Side Effect], maintenance therapy, male, microsatellite instability, monotherapy, multicenter study, nausea/si [Side Effect], outcome assessment, overall survival, phase 2 clinical trial, pneumonia/si [Side Effect], progression free survival, prospective study, pruritus/si [Side Effect], response evaluation criteria in solid tumors, treatment duration, treatment response, triacylglycerol lipase blood level, very elderly, ipilimumab/ae [Adverse Drug Reaction], ipilimumab/ct [Clinical Trial], ipilimumab/cb [Drug Combination], ipilimumab/dt [Drug Therapy], ipilimumab/iv [Intravenous Drug Administration], ipilimumab/pd [Pharmacology], ipilimumab/pv [Special Situation for Pharmacovigilance], nivolumab/ae [Adverse Drug Reaction], nivolumab/ct [Clinical Trial], nivolumab/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29052
JAMA Oncology
LibKey Link

المؤلفون: Wu C.-Y., Zhang Y., Liang L., Wu J., Paton V., Millward M., Keam B., Jameson M., Hou M.-M., Kang Y.-K., Markman B., Lu C.-H., Rau K.-M., Lee K.-H., Horvath L., Friedlander M., Hill A., Sandhu S., Barlow P., Desai J., Deva S., Lee J.S., Lin C.-C., Yen C.-J., Chao Y.

مصطلحات الفهرس: hypercalcemia/si [Side Effect], hyperglycemia/si [Side Effect], hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hyponatremia/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], loss of appetite/si [Side Effect], lower respiratory tract infection/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, maximum tolerated dose, melanoma/dt [Drug Therapy], merkel cell carcinoma/dt [Drug Therapy], microsatellite instability, monotherapy, multiple cycle treatment, nausea and vomiting/si [Side Effect], non small cell lung cancer/dt [Drug Therapy], optimal drug dose, ovary carcinoma/dt [Drug Therapy], pancreas cancer/dt [Drug Therapy], phase 1 clinical trial, pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, rash/si [Side Effect], recommended drug dose, renal cell carcinoma/dt [Drug Therapy], retrospective study, sepsis/si [Side Effect], skin carcinoma/dt [Drug Therapy], small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], time to maximum plasma concentration, treatment response time, triple negative breast cancer/dt [Drug Therapy], upper gastrointestinal bleeding/si [Side Effect], bilirubin/ec [Endogenous Compound], new drug/ct [Clinical Trial], new drug/do [Drug Dose], new drug/dt [Drug Therapy], new drug/to [Drug Toxicity], new drug/iv [Intravenous Drug Administration], new drug/pk [Pharmacokinetics], new drug/pv [Special Situation for Pharmacovigilance], programmed death 1 ligand 1/ec [Endogenous Compound], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cr [Drug Concentration], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/to [Drug Toxicity], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/pk [Pharmacokinetics], tislelizumab/pv [Special Situation for Pharmacovigilance], tislelizumab/tm [Unexpected Outcome of Drug Treatment], immunohistochemical test kit, VENTANA PD-L1 (SP263), maximum concentration, adult, aged, anemia/si [Side Effect], antineoplastic activity, area under the curve, article, ascites/si [Side Effect], backache/si [Side Effect], bile duct carcinoma/dt [Drug Therapy], body weight disorder/si [Side Effect], clinical outcome, cohort analysis, colitis/si [Side Effect], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dosage form comparison, drug dose escalation, drug dose regimen, drug efficacy, drug half life, drug safety, drug tolerability, drug withdrawal, dysphagia/si [Side Effect], dyspnea/si [Side Effect], esophagus cancer/dt [Drug Therapy], esophagus carcinoma/dt [Drug Therapy], fatigue/si [Side Effect], female, follow up, gastrointestinal stromal tumor/dt [Drug Therapy], head and neck squamous cell carcinoma/dt [Drug Therapy], human, hyperbilirubinemia/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29145
Journal for ImmunoTherapy of Cancer
LibKey Link

المؤلفون: Tramontana A.R., Tong S.Y.C., Lye D.C., Yahav D., Sud A., Robinson J.O., Nelson J., Archuleta S., Roberts M.A., Cass A., Paterson D.L., Foo H., Paul M., Guy S.D., Runnegar N., Andresen D.N., Anagnostou N.A., Johnson S.A., Chatfield M.D., Cheng A.C., Fowler V.G., Howden B.P., Meagher N., Price D.J., Van Hal S.J., O'Sullivan M.V.N., Davis J.S., Walls G.B., McBride S., Bak N., Ghosh N., Rogers B.A., Ralph A.P., Davies J., Ferguson P.E., Dotel R., McKew G.L., Gray T.J., Holmes N.E., Smith S., Warner M.S., Kalimuddin S., Young B.E.

مصطلحات الفهرس: vancomycin/iv [Intravenous Drug Administration], vancomycin/pv [Special Situation for Pharmacovigilance], daptomycin/iv [Intravenous Drug Administration], acute kidney failure/si [Side Effect], adult, aged, all cause mortality, article, clinical outcome, controlled study, diarrhea/si [Side Effect], drug efficacy, drug fever/si [Side Effect], drug monitoring, drug safety, female, follow up, general practitioner, hospitalization, human, hypertransaminasemia/si [Side Effect], major clinical study, male, methicillin resistant Staphylococcus aureus infection/dt [Drug Therapy], monotherapy, mortality rate, pilot study, priority journal, randomized controlled trial, rash/si [Side Effect], recurrent disease, therapy effect, thrombocytopenia/si [Side Effect], thrombophlebitis/si [Side Effect], treatment duration, treatment failure, cefazolin/ae [Adverse Drug Reaction], cefazolin/cb [Drug Combination], cefazolin/dt [Drug Therapy], cefazolin/iv [Intravenous Drug Administration], cefazolin/pv [Special Situation for Pharmacovigilance], cloxacillin/ae [Adverse Drug Reaction], cloxacillin/cb [Drug Combination], cloxacillin/dt [Drug Therapy], cloxacillin/iv [Intravenous Drug Administration], cloxacillin/pv [Special Situation for Pharmacovigilance], daptomycin/ae [Adverse Drug Reaction], daptomycin/cb [Drug Combination], daptomycin/dt [Drug Therapy], daptomycin/pv [Special Situation for Pharmacovigilance], flucloxacillin/ae [Adverse Drug Reaction], flucloxacillin/cb [Drug Combination], flucloxacillin/dt [Drug Therapy], flucloxacillin/iv [Intravenous Drug Administration], flucloxacillin/pv [Special Situation for Pharmacovigilance], vancomycin/ae [Adverse Drug Reaction], vancomycin/cb [Drug Combination], vancomycin/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29372
JAMA - Journal of the American Medical Association
LibKey Link

المؤلفون: Chew C.Y., Saracino A.M., Nikpour M., Mar A.

مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
Australasian Journal of Dermatology
LibKey Link

المؤلفون: Wong A.

مصطلحات الفهرس: bone marrow suppression/si [Side Effect], China, coma/si [Side Effect], convulsion/si [Side Effect], coronavirus disease 2019/dt [Drug Therapy], diarrhea/si [Side Effect], drug efficacy, drug overdose, drug research, evidence based medicine, gastrointestinal symptom/si [Side Effect], headache/si [Side Effect], heart arrhythmia/si [Side Effect], human, hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hypotension/si [Side Effect], kidney dysfunction/si [Side Effect], liver injury/si [Side Effect], morbidity, mortality, nonhuman, pancreatitis/si [Side Effect], pandemic, patient safety, priority journal, QT prolongation/si [Side Effect], rash/si [Side Effect], self medication, treatment outcome, virus load, virus transmission, activated carbon/dt [Drug Therapy], azithromycin/ae [Adverse Drug Reaction], drug intoxication/dt [Drug Therapy], azithromycin/cb [Drug Combination], azithromycin/dt [Drug Therapy], azithromycin/pv [Special Situation for Pharmacovigilance], ceftriaxone/cb [Drug Combination], ceftriaxone/dt [Drug Therapy], ceftriaxone/pv [Special Situation for Pharmacovigilance], chloroquine/ae [Adverse Drug Reaction], chloroquine/cb [Drug Combination], chloroquine/do [Drug Dose], chloroquine/dt [Drug Therapy], article, atrioventricular block/si [Side Effect], bleeding/si [Side Effect], chloroquine/pv [Special Situation for Pharmacovigilance], colchicine/do [Drug Dose], colchicine/dt [Drug Therapy], colchicine/to [Drug Toxicity], colchicine/pv [Special Situation for Pharmacovigilance], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/cb [Drug Combination], hydroxychloroquine/do [Drug Dose], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pv [Special Situation for Pharmacovigilance], ivermectin/do [Drug Dose], ivermectin/dt [Drug Therapy], ivermectin/to [Drug Toxicity], lopinavir plus ritonavir/ae [Adverse Drug Reaction], lopinavir plus ritonavir/do [Drug Dose], lopinavir plus ritonavir/dt [Drug Therapy], lopinavir plus ritonavir/to [Drug Toxicity], lopinavir plus ritonavir/pv [Special Situation for Pharmacovigilance], remdesivir/ae [Adverse Drug Reaction], remdesivir/dt [Drug Therapy], remdesivir/pv [Special Situation for Pharmacovigilance], thalidomide/do [Drug Dose], thalidomide/dt [Drug Therapy], thalidomide/to [Drug Toxicity], thalidomide/pv [Special Situation for Pharmacovigilance], tocilizumab/ae [Adverse Drug Reaction], tocilizumab/dt [Drug Therapy], tocilizumab/pv [Special Situation for Pharmacovigilance], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29200
EMA - Emergency Medicine Australasia
LibKey Link